Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

On (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of ...

MG-ADL (Myasthenia Gravis - Activities of Daily Living) provides a rapid clinical assessment of the patient's recall of symptoms impacting activities of daily living, with a total score range of 0 to ...

More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia ...

Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

Cruz opened up about her myasthenia gravis diagnosis on her Instagram page on Sunday, March 23, saying her condition made it difficult for her to build muscles. “It’s been a real roller ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half of 2025. Click here to read more.

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

Generalised myasthenia gravis (gMG) is a chronic disorder in ... Soliris effectively reduces the symptoms of gMG and improves overall muscle function. Previously approved for adults with gMG ...

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized ...